Chong Kun Dang Pharmaceutical Corp. Logo

Chong Kun Dang Pharmaceutical Corp.

185750 | KO

Overview

Corporate Details

ISIN(s):
KR7185750007
LEI:
Country:
South Korea
Address:
서울 서대문구 충정로3가 3가 368 종근당빌딩, 서대문구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

No description available.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 승인)
Korean 7.2 KB
2025-08-22 00:00
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 신청)
Korean 13.5 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 4.9 MB
2025-08-01 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-07-24 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 15.8 KB
2025-06-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.9 KB
2025-06-12 00:00
Regulatory Filings
유형자산취득결정
Korean 7.9 KB
2025-06-12 00:00
Regulatory Filings
풍문또는보도에대한해명(미확정)
Korean 8.0 KB
2025-06-10 00:00
Regulatory Filings
풍문또는보도에대한해명(미확정)
Korean 6.2 KB
2025-06-02 00:00
Governance Information
기업지배구조보고서공시
Korean 1.8 MB
2025-05-22 00:00
Regulatory Filings
기타경영사항(자율공시) (CKD510 기술수출 관련 마일스톤 수령)
Korean 5.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.9 MB
2025-04-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-04-23 00:00
Regulatory Filings
투자판단관련주요경영사항 (듀비엠폴서방정(CKD383) 식품의약품안전처 국내 품목허가 신청)
Korean 16.9 KB
2025-04-23 00:00
Regulatory Filings
투자판단관련주요경영사항 (듀비엠파정(CKD398) 식품의약품안전처 국내 품목허가 신청)
Korean 16.6 KB

Automate Your Workflow. Get a real-time feed of all Chong Kun Dang Pharmaceutical Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chong Kun Dang Pharmaceutical Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chong Kun Dang Pharmaceutical Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Talk to a Data Expert

Have a question? We'll get back to you promptly.